Alectinib is the first ALK inhibitor used in combination with chemotherapy to significantly improve disease-free survival (DFS) compared to platinum chemotherapy alone in a phase III clinical trial for all disease stages of non-small cell lung cancer (NSCLC). These are the results of an analysis carried out within the ALINA study, presented last month at the ESMO Congress, which took place in Madrid. The median follow-up period for study participants was nearly 28 months.
The main conclusions:
survival rates with combination therapy were more than 90%, compared with about 60% in people who received chemotherapy alone survival in the absence of central nervous system disease was improved with the addition of alectinib adverse events were reported in about 30 % of participants in both groups with no grade 5 adverse events present although the proportion of people experiencing severe adverse events was higher in the alectinib group (13% versus 8%), the need for discontinuation of therapy was lower (2% versus 5%)
Targeted therapy offers superior results compared to classical chemotherapy regimens in patients with ALK mutation-positive metastatic NSCLC. To date, there has been little data on the effectiveness of the therapy in people whose tumor has been surgically removed. Patients with ALK-positive NSCLC often have CNS recurrences following resection. Identifying an effective therapy not only on localized but also distant disease is an important step.
The data presented represent an early analysis from the ALINA study, with continued long-term follow-up of study participants to assess the impact of adjuvant alectinib therapy on prognosis. It is also necessary to investigate the effects of alectinib according to the types of ALK mutations and to identify, if any, specific genetic changes that indicate favorable response to this therapy or not.
Read also:
2023-11-29 09:04:01
#ESMO23 #Adjuvant #alectinib #therapy #prolongs #survival #patients #completely #resected #ALK #mutationpositive #NSCLC #Sentinel #Report
